Tejabhiram Yadavalli
Department of Ophthalmology and Visual Sciences
University of Illinois at Chicago
I am currently a senior postdoctoral fellow in your department at UIC, under the mentorship of Prof. Deepak Shukla, a stalwart in the field of herpes virology. I joined this current position in early 2016, immediately after finishing my PhD in material science and nanotechnology focusing on the development of novel Drugs and Drug Delivery Systems. With an undergraduate degree in biotechnology and strong desire to work in the field of nanotechnology, I chose to work with my current mentor such that I could work with the state-of-the-art nanomachines, viruses. Having a professional degree in material science has definitely given me the advantage of an outsider’s perspective to existing biomedical problems. During my PhD, I extensively worked on the development of a pH and temperature responsive magnetic drug delivery system; the article resulting from this work was published in a society journal (Yadavalli et al, JMMM, 2014) and remains to be one of my highest cited articles. Another good example of this is discussed in my latest article where I improved the topical delivery of HSV antiviral using a relatively simple carbon-based sustained release platform (Yadavalli et al, Sci Adv, 2019). This publication not only garnered national media interest but also has sparked the attention of multiple industry giants to invest in my project. However, these outcomes would not have been possible without the constant support and rigorous training I received at the current lab where I published several other articles on the development and testing of antiviral drugs (Yadavalli et al. Mol. Ther. Nuc. Acids 2017; Jaishankar et al. eaan5861, Sci. Trans. Med, 2018).
Could zinc oxide tetrapod nanoparticles be used as an effective immunotherapy against HSV-2?
Nanomedicine (London, England) 09, 2016 | Pubmed ID: 27527812
Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections.
Nanomedicine : nanotechnology, biology, and medicine 01, 2017 | Pubmed ID: 27575283
Cultured corneas show dendritic spread and restrict herpes simplex virus infection that is not observed with cultured corneal cells.
Scientific reports 02, 2017 | Pubmed ID: 28198435
Zinc oxide tetrapods inhibit herpes simplex virus infection of cultured corneas.
Molecular vision , 2017 | Pubmed ID: 28275313
Emerging Roles of Heparanase in Viral Pathogenesis.
Pathogens (Basel, Switzerland) Sep, 2017 | Pubmed ID: 28927006
Targeting Herpes Simplex Virus-1 gD by a DNA Aptamer Can Be an Effective New Strategy to Curb Viral Infection.
Molecular therapy. Nucleic acids Dec, 2017 | Pubmed ID: 29246315
Herpesvirus-encoded microRNAs detected in human gingiva alter host cell transcriptome and regulate viral infection.
Biochimica et biophysica acta. Gene regulatory mechanisms May, 2018 | Pubmed ID: 29550353
Host Enzymes Heparanase and Cathepsin L Promote Herpes Simplex Virus 2 Release from Cells.
Journal of virology 12, 2018 | Pubmed ID: 30232188
Drug-encapsulated carbon (DECON): A novel platform for enhanced drug delivery.
Science advances 08, 2019 | Pubmed ID: 31453334
Current and Emerging Therapies for Ocular Herpes Simplex Virus Type-1 Infections.
Microorganisms Oct, 2019 | Pubmed ID: 31658632
Prior inhibition of AKT phosphorylation by BX795 can define a safer strategy to prevent herpes simplex virus-1 infection of the eye.
The ocular surface 04, 2020 | Pubmed ID: 31770600
Heparanase-Regulated Syndecan-1 Shedding Facilitates Herpes Simplex Virus 1 Egress.
Journal of virology 02, 2020 | Pubmed ID: 31827001
Cytomegalovirus Retinitis in HIV and Non-HIV Individuals.
Microorganisms Dec, 2019 | Pubmed ID: 31905656
Bacterial Pigment Prodigiosin Demonstrates a Unique Antiherpesvirus Activity That Is Mediated through Inhibition of Prosurvival Signal Transducers.
Journal of virology 06, 2020 | Pubmed ID: 32295926
BX795 demonstrates potent antiviral benefits against herpes simplex Virus-1 infection of human cell lines.
Antiviral research 08, 2020 | Pubmed ID: 32380150
Vaccines and Therapies in Development for SARS-CoV-2 Infections.
Journal of clinical medicine Jun, 2020 | Pubmed ID: 32560227
and Activity, Tolerability, and Mechanism of Action of BX795 as an Antiviral against Herpes Simplex Virus 2 Genital Infection.
Antimicrobial agents and chemotherapy 08, 2020 | Pubmed ID: 32601167
Infection-Induced Porcine Ex Vivo Corneal Wound Model to Study the Efficacy of Herpes Simplex Virus-1 Entry and Replication Inhibitors.
Methods in molecular biology (Clifton, N.J.) , 2021 | Pubmed ID: 32808270
Pharmaceutically Acceptable Carboxylic Acid-Terminated Polymers Show Activity and Selectivity against HSV-1 and HSV-2 and Synergy with Antiviral Drugs.
ACS infectious diseases 11, 2020 | Pubmed ID: 33078609
Standalone or combinatorial phenylbutyrate therapy shows excellent antiviral activity and mimics CREB3 silencing.
Science advances Dec, 2020 | Pubmed ID: 33277262
The 3--sulfation of heparan sulfate modulates protein binding and lyase degradation.
Proceedings of the National Academy of Sciences of the United States of America 01, 2021 | Pubmed ID: 33441484
Herpes Simplex Virus Cell Entry Mechanisms: An Update.
Frontiers in cellular and infection microbiology , 2020 | Pubmed ID: 33537244
Pathobiology and treatment of viral keratitis.
Experimental eye research 04, 2021 | Pubmed ID: 33556334
Disruption of innate defense responses by endoglycosidase HPSE promotes cell survival.
JCI insight 04, 2021 | Pubmed ID: 33621216
Entry receptor bias in evolutionarily distant HSV-1 clinical strains drives divergent ocular and nervous system pathologies.
The ocular surface Jul, 2021 | Pubmed ID: 33766740
Prophylactic treatment with BX795 blocks activation of AKT and its downstream targets to protect vaginal keratinocytes and vaginal epithelium from HSV-2 infection.
Antiviral research Oct, 2021 | Pubmed ID: 34303747
OPTN is a host intrinsic restriction factor against neuroinvasive HSV-1 infection.
Nature communications Sep, 2021 | Pubmed ID: 34518549
Porcine Corneal Tissue Explant to Study the Efficacy of Herpes Simplex Virus-1 Antivirals
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved